Rare Protein Detection on Cell Surfaces: Ultrasensitive Detection of B-Cell Chron
Small Business Information
JADEN BIOSCIENCE, INC.
3950 SORRENTO VALLEY BLVD, SUITE 400, SAN DIEGO, CA, -
AbstractDESCRIPTION (provided by applicant): The ROR1 cell surface biomarker is expressed on B-cell Chronic Lymphocytic Leukemia (B-CLL) cells but not on healthy B-cells or other white blood cells (WBCs) in B-CLL patients. We propose to develop an inexpensive, eas y-to-use, rapid, ultrasensitive assay specific for ROR1 for the detection and monitoring of B- CLL from a single drop of blood. Our goal is to attain detection levels better than currently available methods, the most sensitive flow cytometry (MRD-FC) or eq ual to polymerase chain reaction (ASO-PCR) methods available to detect Minimal Residual Disease (MRD). Early detection of MRD is critical in managing therapy and detecting the emergence of drug resistant malignancies. Current methods are expensive with reg ard to instruments, reagents, and the need for highly trained technicians. Moreover, FC methods do not adequately differentiate between B-CLL and other clonal B-cell malignancies such as mantle cell lymphoma and splenic marginal zone lymphoma. Current test s require venipuncture to collect 1-3 mLs of blood and the time to results are hours for FC and a week for ASO-PCR. JBI possesses a platform technology to address these shortcomings. JBI's first use of its technology resulted in the ZivaTM Ultrasensitive B rdU Cell Proliferation assay. Using only 50 lt L of sample, Ziva detected 1-4 proliferating cells among 105 non-proliferating cells, a claim others have not approached. Applying this level of sensitivity to the detection of B-CLL would make it an attractiv e competitor to ASO-PCR, the most sensitive method. However, unlike ASO-PCR that takes one week to perform and is very expensive, the Ziva assay can be performed in 1 hour from a single drop of blood and is inexpensive. Together with the use of ROR1, a spe cific biomarker or B-CLL, if successful the resulting assay could differentiate between B-CLL and other clonal B-cell malignancies. Preliminary data show that an early-stage adaptation of our technology yielded an almost 2-fold better sensitivity than 4-co lor FC. We anticipate further improvements using our assay development strategies. Where standard FC methods for monitoring disease progression require 1-3 mL of blood collected by venipunture, JBI's assay proposes using a finger prick to collect a blood s ample which represents a far more convenient method of sample collection for routine monitoring of patients. If successful the proposed test will be more sensitive and specific than FC and reduce the overall cost burden of patient management. Our approach focuses on three specific aims: AIM 1: To develop cell surface assay model systems using cells with known surface markers. AIM 2: To develop and optimize the analytical performance of the ROR1/CLL pilot assay using cell lines. AIM 3: To preliminarily evalu ate the ROR1/CLL assay performance characteristics using clinically relevant samples. PUBLIC HEALTH RELEVANCE: This grant proposes to develop an ultrasensitive, inexpensive, easy-to-use, rapid diagnostic assay, that is specific for the detection of the ROR1 cell surface biomarker on B-CLL cells, for the detection and monitoring of B-cell Chronic Lymphocytic Leukemia (B-CLL) using a single drop of blood. Developing rapid, inexpensive and easy-to-use diagnostic tools that are better in sensitivity than the most sensitive flow cytometry or PCR methods, using a single drop of blood, presents a very broad public health benefit; for basic cancer research and for patient management worldwide. Furthermore, successful completion of this project is expected to result in a more useful method to differentially diagnose B-CLL from other clonal B cell malignancies such as mantle cell lymphoma and splenic marginal zone lymphoma. The SBIR funds requested in this proposal will accelerate the introduction of an importan t new technology for the detection of rare cell surface markers for use in both the research and medical communities.
* information listed above is at the time of submission.